ArticleThe Kaohsiung journal of medical sciences2021
Oncogenic miRNA-1908 targets HDAC10 and promotes the aggressive phenotype of cervical cancer cell.
Article in The Kaohsiung journal of medical sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 16 citations in OpenAlex.
- Downregulation of miR-3074-5p slows cervical cancer progression by targeting TGFBR2 expression.Irish journal of medical science · 2026Article
- Clinical relevance and mechanistic investigation of miR-1908-5p as a prognostic biomarker in colorectal cancer.Hereditas · 2026Article
- The role and diagnostic value of deregulated miRNAs in cervical cancer.Discover oncology · 2025Review
- circ_0000337 Promotes the Progression of Cervical Cancer by miR-155-5p/RAB3B Axis.Biochemical genetics · 2024Article
- Prediction of miRNA‑mRNA network regulating the migration ability of cytarabine‑resistant HL60 cells.Biomedical reports · 2024Article
- The circCDK17/miR-122-5p/ASF1B axis regulates the progression of cervical cancer.Histology and histopathology · 2023Article
- Fatty acid metabolism: A new therapeutic target for cervical cancer.Frontiers in oncology · 2023Review
- miR-1908: a microRNA with diverse functions in cancers and non-malignant conditions.Cancer cell international · 2022Review
- Differential molecular mechanistic behavior of HDACs in cancer progression.Medical oncology (Northwood, London, England) · 2022Review
- miR-1908 Dysregulation in Human Cancers.Frontiers in oncology · 2022Review
- HDAC10 Inhibits Cervical Cancer Progression through Downregulating the HDAC10-microRNA-223-EPB41L3 Axis.Journal of oncology · 2022Article
- Oncogenic miRNA-1908 targets HDAC10 and promotes the aggressive phenotype of cervical cancer cell.The Kaohsiung journal of medical sciences · 2021Article
- Loss of Deacetylation Enzymes Hdac6 and Sirt2 Promotes Acetylation of Cytoplasmic Tubulin, but Suppresses Axonemal Acetylation in Zebrafish Cilia.Frontiers in cell and developmental biology · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
MicroRNAs (miRNAs) have vital functions in tumorigenesis and cancer progression. The significance of miR-1908 in cervical cancer has not been determined. We revealed that miR-1908 was notably upregulated in cervical cancer. Upregulation of miR-1908 increased cervical carcinoma cell growth and invasion. Downregulation of miR-1908 caused the opposite effects. We confirmed that histone deacetylase 10 (HDAC10) was a potential target of miR-1908 using bioinformatics analysis and luciferase reporter gene assays. Western blot analysis showed that miR-1908 regulated the expression of HDAC10 by binding its 3'-UTR. In addition, ectopic expression of HDAC10 partially reversed the promoting effects of miR-1908. In conclusion, our findings indicated that miR-1908 targets HDAC10 in cervical cancer and regulates aggressive cervical cancer cell phenotypes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.